KRN7000 Applications

KRN7000 has wide research and human therapeutic applications. Below are a few examples of current research being applied with KRN7000.

Multiple sclerosis application: Synthetic glycolipid ligands as novel therapeutics for multiple sclerosis

Adjuvant application: Adjuvant effect of alpha-galactosylceramide (alpha-GalCer) in mice upon intravenous administration of antigen plus alpha-GalCer.

Adjuvant effects of alpha-GalCer by Riken RCAI

 

Arthritis application: Activation of invariant NKT cells confers protection against Chlamydia trachomatis-induced arthritis

Diabetes application: NKT cell activation by Alpha-galactosylceramide (Alpha-GalCer) inhibits autoimmune diabetes in NOD mice

Hepatic application: Preactivation of NKT cells with Alpha-GalCer protects against hepatic ischemia-reperfusion injury in mouse by a mechanism involving IL-13 and adenosine A2A receptor

Diabetes type 1 application: Alpha-GalCer C20:2 May be a More Efficacious Candidate Drug Than alpha-GalCer C26:0 (KRN7000) for iNKT Cell Mediated Protection from Type 1 Diabetes

Head and neck carcinoma application: Combination therapy of in vitro-expanded natural killer T cells and alpha-galactosylceramide-pulsed antigen-presenting cells in patients with recurrent head and neck carcinoma.

Lupus application: Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus

Adjuvant application: The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.

Influenza A virus application: Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection

Hepatic application: Activated liver dendritic cells generate strong acquired immunity in alpha-galactosylceramide treatment.

Lung cancer application: A Phase I Study of Alpha-Galactosylceramide (KRN7000)–Pulsed Dendritic Cells in Patients with Advanced and Recurrent Non–Small Cell Lung Cancer

Rheumatoid arthritis application: Activation of invariant NK T cells protects against experimental rheumatoid arthritis by an IL-10-dependent pathway

Ovarian tumor application: Alpha-Galactosylceramide enhances the protective and therapeutic effects of tumor cell based vaccines for ovarian tumors

Colon cancer application: Antitumor effect of whole body hyperthermia with alpha-galactosylceramide in a subcutaneous tumor model of colon cancer

Leukemia application: Evaluation of the function of human invariant NKT cells from cancer patients using alpha-galactosylceramide-loaded murine dendritic cells

Tuberculosis application: Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin

Tuberculosis application: Activation of NKT cells protects mice from tuberculosis

Dendritic cell application: Antitumor cytotoxicity mediated by ligand-activated human V alpha24 NKT cells

Sarcoidosis application: Impaired IFN-gamma production of Valpha24 NKT cells in non-remitting sarcoidosis

Colorectal cancer application: Treatment of hepatic metastasis of the Colon26 adenocarcinoma with an α-galactosylceramide, KRN7000

Antimicrobial application: Cd1d-dependent regulation of bacterial colonization in the intestine of mice

Breast cancer application: Alpha-Galactosylceramide (KRN7000) suppression ofchemical- and oncogene-dependent carcinogenesis

Experimental autoimmune uveitis application: Activation of iNKT Cells Amerilorates Experimental Ocular Autoimmunity by a Mechanism Involving Innate IFN-γ Production and Dapening of the Adadtive Th1 and Th17 Responses

Colitis application: Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice

Human T-lymphotropic virus type 1 (HTLV-1) application: Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders

Malaria and Melanoma applications: Superior Protection against Malaria and Melanoma Metastases by a C-glycoside Analogue of the Natural Killer T Cell Ligand Alpha-Galactosylceramide

Asthma application: Alpha-galactosylceramide-induced iNKT cells suppress experimental allergic asthma in sensitized mice: role of IFN-gamma

NKT cells identified in other animals: Functional iNKT cells found in other animals: Functional CD1d and/or NKT cell invariant chain transcript in horse, pig, African elephant and guinea pig, but not in ruminants

Resistance against tumor cells research: Tumor cells loaded with alpha-galactosylceramide induce innate NKT and NK cell-dependent resistance to tumor implantation in mice

Immunology research: Multiple innate signaling pathways cooperate with CD40 to induce potent, CD70-dependent cellular immunity

Immune regulation derivative research: Induction of Th1-biased cytokine production by Alpha-carba-GalCer, a neoglycolipid ligand for NKT cells

Nanoparticles without inducing anergy research: Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

Gaucher disease research: Uncoupling between CD1d upregulation induced by retinoic acid and conduritol-B-epoxide and iNKT cell responsiveness

Fatty acid amide hydrolase research: Fatty acid amide hydrolase shapes NKT cell responses by influencing the serum transport of lipid antigen in mice

Atherosclerosis research: Effect of natural killer T cell activation on the initiation of atherosclerosis

Radiation protection research: alpha-Galactosylceramide (AGL-517) treatment protects mice from lethal irradiation

Transplantation research: Valpha14 NK T cell-triggered IFN-gamma production by Gr-1+CD11b+ cells mediates early graft loss of syngeneic transplanted islets

Myasthenia gravis (EAMG) research: Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia

Back to top

 

rolex replica sale | rolex replica uk | tag heuer replica | rolex replica

New 7DW8-5 glycolipid

7DW8-5

Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch

 

Meet Funakoshi Company
at the following meetings:

The 21st Annual Meeting of Japanese Assocation of Cancer Immunology
Chiba, Japan
June 28-30, 2017

The Japanese Society for Genome Editing
Osaka, Japan
June 28-30, 2017

The 36th Annual Meeting of Japanese Association of Forensic Toxicology
July 6-7, 2017

The 76th Annual Meeting of the Japanese Cancer Association
Yokohama, Japan
September 28-30, 2017

NIH Festival
Bethesda, Maryland
September 2017

ASCB
Philadelphia, PA
December 2-6, 2017